I am a Senior Project Leader in 呼吸, 炎症与自身免疫(RIA), 澳门第一赌城在线娱乐R&D.

I lead multi-disciplinary respiratory research and development projects in pre-clinical and clinical phase. Several of these projects are international collaborations with pharmaceutical/biotech partners. 2011 - 2013年, I was Business 操作 Director for early RIA and responsible for the smooth-running of the unit, 约有200名员工. This included orchestrating governance through the RIA 研究 Board ensuring timely, high quality decision-making in support of project progression.

Previously, I was Senior Project Manager in RIA, from 2009 to 2011. 在此期间, I was Chairperson/deputy of the Local Project Forum, 带上直线经理, project leaders and senior scientists together to manage and support drug discovery projects. I was also member of the 研究 Area Portfolio Team (RAPT) responsible for implementing strategy and managing the size and shape of the RIA discovery project portfolio.

In 2004, I was made Director of Lead Generation Biology, a post I held for five years following my previous position as Associate Director. I managed the Lead Generation Biology section of approximately 30 staff and was jointly responsible for the delivery of lead series.

1990年至2001年, I was a pre-clinical project leader within the Gastrointestinal, Cardiovascular 研究 Area at AstraZeneca, Molndal, Sweden where I was responsible for establishing drug discovery projects in the novel area of osteoporosis and bone biology. A key area of focus was the osteoclast acid pump.

I started my career in the pharmaceutical industry in the UK at SmithKline & French where I worked as lead biochemist in the drug discovery project leading to the approval of a gastric acid inhibitor.

I am driven by scientific curiosity and an ambition to understand the biology underlying disease that will allow us bring new, innovative medicines to patients in need.

大卫·基林 Senior Project Leader, 研究 and Early 发展, RIA, 澳门第一赌城在线娱乐R&D

最新的项目

New approaches to the treatment of asthma with inhaled biologics

发表的文章

Demonstrated that the vacuolar acid pump in the osteoclast, responsible for the breakdown of bone, was different to that in other tissues. This allowed the possibility of selective inhibition to treat osteoporosis.

发表的文章

Defined the mechanism of action of the gastric acid inhibitor, omeprazole. One of the first to publish the complex mechanism of this drug.

  特色的出版物

奥美拉唑的作用机理

基林 DJ, Fallowfield C, Milliner KJ, Tingley SK, Ife RJ, Underwood AH. Studies on the mechanism of action of omeprazole. 生化药理学，1985. 34(16): p. 2967-73.

液泡质子泵的缺陷

Frattini A, Orchard PJ, Sobacchi C et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. 自然遗传学. 2000. 25(3):343-346

阅读更多

Components of successful lead generation

Davis AM, 基林 DJ, Steele J, Tomkinson NP, Tinker A. Components of successful lead generation. Current Topics in Medicinal Chemistry 2005. 5 (4): 421-439.

阅读更多
澳门第一赌城在线娱乐的人民

澳门第一赌城在线娱乐的人民 share a common purpose: to push the boundaries of science to deliver life-changing medicines.

澳门在线赌城娱乐

Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.

澳门第一赌城在线娱乐公司

澳门第一赌城在线娱乐是全球性的, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

加入澳门在线赌城娱乐

and help us deliver life-changing medicines 

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.

澳门在线赌城娱乐的职业